HomeCompareTTTSF vs ABBV

TTTSF vs ABBV: Dividend Comparison 2026

TTTSF yields 32520.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TTTSF wins by $6.591363113035332e+21M in total portfolio value
10 years
TTTSF
TTTSF
● Live price
32520.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.591363113035332e+21M
Annual income
$6,551,731,750,418,625,000,000,000,000.00
Full TTTSF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TTTSF vs ABBV

📍 TTTSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTTTSFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TTTSF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TTTSF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TTTSF
Annual income on $10K today (after 15% tax)
$2,764,227.64/yr
After 10yr DRIP, annual income (after tax)
$5,568,971,987,855,831,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TTTSF beats the other by $5,568,971,987,855,831,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TTTSF + ABBV for your $10,000?

TTTSF: 50%ABBV: 50%
100% ABBV50/50100% TTTSF
Portfolio after 10yr
$3.295681556517666e+21M
Annual income
$3,275,865,875,209,312,000,000,000,000.00/yr
Blended yield
99.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TTTSF
No analyst data
Altman Z
-367.5
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TTTSF buys
0
ABBV buys
0
No recent congressional trades found for TTTSF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTTTSFABBV
Forward yield32520.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$6.591363113035332e+21M$102.3K
Annual income after 10y$6,551,731,750,418,625,000,000,000,000.00$24,771.77
Total dividends collected$6.588756718499505e+21M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TTTSF vs ABBV ($10,000, DRIP)

YearTTTSF PortfolioTTTSF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$3,262,733$3,252,032.52$11,550$430.00+$3.25MTTTSF
2$995,127,784$991,636,659.93$13,472$627.96+$995.11MTTTSF
3$283,725,972,382$282,661,185,653.70$15,906$926.08+$283725.96MTTTSF
4$75,622,256,343,115$75,318,669,552,665.94$19,071$1,382.55+$75622256.32MTTTSF
5$18,842,495,420,268,596$18,761,579,605,981,460.00$23,302$2,095.81+$18842495420.25MTTTSF
6$4,389,084,664,127,597,000$4,368,923,194,027,908,600.00$29,150$3,237.93+$4389084664127.57MTTTSF
7$955,796,299,651,993,000,000$951,099,979,061,376,600,000.00$37,536$5,121.41+$955796299651993.00MTTTSF
8$194,590,799,244,701,040,000,000$193,568,097,204,073,430,000,000.00$50,079$8,338.38+$194590799244701056.00MTTTSF
9$37,038,656,651,127,954,000,000,000$36,830,444,495,936,120,000,000,000.00$69,753$14,065.80+$37038656651127955456.00MTTTSF
10$6,591,363,113,035,332,000,000,000,000$6,551,731,750,418,625,000,000,000,000.00$102,337$24,771.77+$6.591363113035332e+21MTTTSF

TTTSF vs ABBV: Complete Analysis 2026

TTTSFStock

TruTrace Technologies Inc. ideates, architects, designs, develops, and deploys a software platform in Canada. It offers TruTrace, a cloud-based blockchain software that connects quality control and inventory management for food, pharma, cosmetics, and agroscience industries to track products from manufacturing to sale. The company also provides StrainSecure, a cloud-based blockchain software that connects quality control and inventory testing for hemp, CBD, and cannabis companies to track products from genome to sale. Its platform is also used to store, manage, share, access quality assurance, testing details, and certificates of authenticity, as well as motion and movement intelligence on inventory from batches and lots to serialized items. The company was incorporated in 2011 and is headquartered in Toronto, Canada.

Full TTTSF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TTTSF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TTTSF vs SCHDTTTSF vs JEPITTTSF vs OTTTSF vs KOTTTSF vs MAINTTTSF vs JNJTTTSF vs MRKTTTSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.